AlphaGrep UK
BMRN icon

AlphaGrep UK’s BioMarin Pharmaceuticals BMRN Stock Holding History

AlphaGrep UK’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-5,851
Closed -$335K – 767
2026
Q2 		$335K Buy
5,851
+1,145
+24% +$62.7K 0.1% 409
2026
Q1 		$266K Buy
+4,706
New +$274K 0.08% 568

Other funds holding BMRN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

AlphaGrep UK's BMRN Position: Q3 2026 in Review

AlphaGrep UK sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2026, closing a stake of 5,851 shares — an estimated $335K sold.

AlphaGrep UK first reported a position in BMRN in Q1 2026 and held it in 2 quarters. The position peaked at $335K in Q2 2026. 434 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • AlphaGrep UK reported no remaining BioMarin Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • AlphaGrep UK sold 5,851 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $335K.
  • AlphaGrep UK first reported a position in BioMarin Pharmaceuticals in Q1 2026 and held it in 2 quarters.
  • AlphaGrep UK's BioMarin Pharmaceuticals position peaked at $335K in Q2 2026.
  • 434 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.